This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Moleculin Biotech’s 8K filing here.
Moleculin Biotech Company Profile
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
Featured Stories
- Five stocks we like better than Moleculin Biotech
- 10 Best Airline Stocks to Buy
- NVIDIA Deal Ignites Aurora Stock’s Explosive Potential
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Why AMD Stock Might Already Be This Year’s Best Buy
- Ride Out The Recession With These Dividend Kings
- 3 Promising Penny Stocks to Watch for Long-Term Gains in 2025
